RecruitingPhase 2NCT07446309

Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults

A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Continuous Intravenous Infusion of HRS-9190 Versus Cisatracurium for Maintaining Neuromuscular Blockade During General Anesthesia in Adults Undergoing Elective Surgery.


Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

60 participants

Start Date

Apr 10, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium. The primary objective is to measure the duration from cessation of the study drug infusion until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include onset time, duration of action, total time of adequate muscle relaxation during surgery, and neuromuscular recovery pattern.. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Able and willing to provide a written informed consent
  • Subjects requiring elective general anesthesia surgery
  • Meet specified age and body mass index (BMI) criteria
  • Conform to the ASA Physical Status Classification
  • Use of highly effective contraception for a specified period if applicable

Exclusion Criteria12

  • Scheduled for specific high-risk surgical procedures
  • History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
  • History of conditions affecting drug metabolism or anesthesia risk
  • Abnormal laboratory values indicating significant clinical abnormalities
  • Positive serology for specified infectious diseases
  • Known hypersensitivity to related medications
  • Recent use of medications interfering with neuromuscular function
  • History of mental illness, cognitive impairment, or epilepsy
  • Participation in another clinical trial within a specified period
  • Any other condition deemed unsuitable by the investigator
  • Pregnant or nursing women
  • Unwilling to use birth control during the specified period

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS-9190; under Inhalational Anesthesia

HRS-9190; under Inhalational Anesthesia

DRUGHRS-9190; under Intravenous Anesthesia

HRS-9190; under Intravenous Anesthesia

DRUGCisatracurium (under Inhalational Anesthesia).

Cisatracurium (under Inhalational Anesthesia).

DRUGCisatracurium (under Intravenous Anesthesia)

Cisatracurium (under Intravenous Anesthesia)


Locations(2)

ZhongShan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Shanxi Provincial People'S Hospital

Taiyuan, Shanxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07446309


Related Trials